Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, Petry U, Dallenbach-Hellweg G, Schmidt D, von Knebel Doeberitz M
Division of Molecular Diagnostics and Therapy, Department of Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany.
Int J Cancer. 2001 Apr 15;92(2):276-84. doi: 10.1002/ijc.1174.
Cytological screening for cervical cancer or its precursors using Papanicolaou's smear test (Pap test) has been highly efficient to reduce the morbidity and mortality of cervical cancer. However, evaluation of the Pap test relies on subjective diagnostic parameters and is affected by a high rate of false-positive and false-negative results. More objective diagnostic parameters to identify truly dysplastic or neoplastic cells in cervical smears as well as in cervical biopsy samples would therefore avoid insecurity for many patients and the high screening costs associated with repeated testing. Cervical dysplasia is induced by persistent infections through high-risk types of human papillomaviruses (HPVs). Outgrowth of dysplastic lesions is triggered by increasing expression of two viral oncogenes, E6 and E7, which both interact with various cell cycle-regulating proteins. Among these is the retinoblastoma gene product pRB, which is inactivated by E7. pRB inhibits transcription of the cyclin-dependent kinase inhibitor gene p16(INK4a). Increasing expression of the viral oncogenes in dysplastic cervical cells might thus be reflected by increased expression of p16(INK4a). In line with this hypothesis, we observed marked overexpression of p16(INK4a) in all cervical intraepithelial neoplasm (CIN) I lesions (n = 47) except those associated with low-risk HPV types (n = 7), all CIN II lesions (n = 32), all CIN III lesions (n = 60) and 58 of 60 invasive cervical cancers. In contrast, no detectable expression of p16(INK4a) was observed in normal cervical epithelium (n = 42), inflammatory lesions (n = 48) and low-grade cervical lesions (CIN I) associated with low-risk HPV types (n = 7). Dysplastic cells could also be identified in cervical smears using a specific p16(INK4a) monoclonal antibody. These data demonstrate that p16(INK4a) is a specific biomarker to identify dysplastic cervical epithelia in sections of cervical biopsy samples or cervical smears.
使用巴氏涂片检查(Pap 检测)对宫颈癌或其癌前病变进行细胞学筛查,在降低宫颈癌的发病率和死亡率方面一直非常有效。然而,Pap 检测的评估依赖于主观诊断参数,且受高假阳性和假阴性结果率的影响。因此,在宫颈涂片以及宫颈活检样本中识别真正发育异常或肿瘤性细胞的更客观诊断参数,将避免许多患者的不安全感以及与重复检测相关的高筛查成本。宫颈发育异常是由高危型人乳头瘤病毒(HPV)持续感染引起的。发育异常病变的生长是由两种病毒癌基因 E6 和 E7 表达增加触发的,这两种基因都与多种细胞周期调节蛋白相互作用。其中包括视网膜母细胞瘤基因产物 pRB,它被 E7 灭活。pRB 抑制细胞周期蛋白依赖性激酶抑制剂基因 p16(INK4a)的转录。发育异常宫颈细胞中病毒癌基因表达的增加可能因此通过 p16(INK4a)表达的增加来反映。与这一假设一致,我们观察到除了与低危型 HPV 相关的病变(n = 7)外,所有宫颈上皮内瘤变(CIN)I 级病变(n = 47)、所有 CIN II级病变(n = 32)、所有 CIN III级病变(n = 60)以及 60 例浸润性宫颈癌中的 58 例均有明显的 p16(INK4a)过表达。相比之下,在正常宫颈上皮(n = 42)、炎症性病变(n = 48)以及与低危型 HPV 相关的低级别宫颈病变(CIN I)(n = 7)中未观察到可检测到的 p16(INK4a)表达。使用特异性 p16(INK4a)单克隆抗体也可在宫颈涂片中识别发育异常细胞。这些数据表明,p16(INK4a)是在宫颈活检样本切片或宫颈涂片中识别发育异常宫颈上皮的特异性生物标志物。